SCID mice are a model of human severe combined immunodeficiency disease and are deficient in B cell function in addition to T cell function. Tumors from other species are easily transplanted into SCID mice and will grow without being rejected. We previously reported that the chemokine BRAK/CXCL14 is expressed in normal cells but its expression is down regulated in an in vitro cancer progression model, suggesting that it has the potential for antitumor activity. Here we report that the growth of BRAK/CXCL14 expression vector-transfected oral cancer cells was completely (100%) suppressed in SCID mouse xenografts even though mock-vector introduced control tumor cells grew well with 100% of animals developing tumors. In addition, suppression of xenografts was much faster and the rate was much higher in SCID mice than in T cell functiondeficient nude mice. These data indicate the possibility that BRAK expression inhibits tumor cell establishment by regulating interactions between tumor stem cells and NK cells and/or suppressing formation of tumor microvessels.
Tumors develop in multiple steps (6, 19, 25) , and tumor progression is dependent on the balance of the expression between tumor progression-promoting and -suppressing genes being in favor of the former at each step (1, 2) . In order to prevent tumor progression, many investigators have searched for molecules that are over-expressed during tumor progression as target molecules for therapeutic drugs and have tried to prevent tumor progression by inhibiting these tumor-promoting molecules. However, drugs for many of the target molecules were not successful for clinical applications owing to the serious side effects of these drugs, which is not surprising because these target molecules are also important for normal development and maintenance of tissues and for homeostasis of our body (16, 22) .
On the other hand, activation of presumptive tumor suppressor(s) or inhibition of their down-regulation may be much more promising for the prevention of tumor progression without significant side effects, because these molecules are supposedly present abundantly in normal tissues. In the course of our study to find an endogenous tumor suppressor(s) for oral cancers (OC), we searched for molecules down-regulated in OC cells when the cells were treated with epidermal growth factor (EGF), whose receptor is frequently overactivated in OC. The expression of BRAK, which is also known as CXC chemokine ligand 14 (CXCL14), was down-regulated significantly by the treatment of OC cells with EGF as observed by cDNA microarray analysis followed by reverse-transcriptase polymerase chain reaction analysis. In order to investigate whether BRAK/CXCL14 have a tumor-suppressing effect in vivo, we prepared BRAK/CXCL14-expression vector-transfected tongue tumor-derived cells (HSC-3 BRAK) and cloned them. No difference in the growth rates of these cells was observed in vitro lower than that of HSC-3 Mock (P < 0.001). In addition, the tumors formed in vivo by the HSC-3 BRAK cells were significantly smaller than those of the mock vector-transfected ones. By 27 days after xenografting, there was no tumor observed when HSC-3 BRAK cells were injected (Fig. 2, C and D) . In these experiments, tumors less than 5 mm 3 in volume were regarded as nonimplanted (suppressed). In fact, only fat tissues and/or scar tissues were observed in the injected sites; and no tumor cells were detected by histological examination of the remnant tissues. These results indicate that BRAK/CXCL14 is a chemokine, having a tumor suppressive activity toward tumor progression of OC in SCID mice. All nude mice are T cell deficient and accept tumors derived from some of other species. We inoculated HSC-3 BRAK or HSC-3 Mock cells subcutaneously into both sides of the back region of 10 female nude mice (BALB/cAJcl-nu-nu; Clea Japan, Tokyo) and compared implantability of xenografts with those of SCID mice. Implantability of HSC-3 Mock cells was 100% at day 3 after tumor cell injection both SCID and nude mice; but after 27 days, only 80% of tumor cells retained in nude mice, being lower than the 100% for the SCID mice (Table 1). In contrast, in the case of BRAK-expressing tumor cells in the SCID mice, only 35% of xenografts retained at day 3 after tumor cell injection, which percentage was significantly lower than that for the nude mice (100%). In addition, no BRAKexpressing tumor cells were detected in SCID mice culture conditions, indicating that BRAK/CXCL14 expression did not affect the growth of the cells in vitro (13) . In this study, we injected 3 clones of BRAKexpressing (HSC-3 BRAK) and 10 clones of mock vector-transfected (HSC-3 Mock, 5 × 10 6 / site) cells prepared as described previously (13), into both sides of the back region of 6-weeks old 10 female SCID mice (FOX CHASE SCID, C.B.-17/lcr-scid/ scidJcl; Clea Japan, Tokyo), respectively. The HSC-3 BRAK cells were shown by western blotting to express a 10 times higher amount of BRAK/ CXCL14 protein than HSC-3 Mock cells. SCID mice used were confirmed not to be leaky by the determination of immunoglobulin production at age of 6 weeks. Tumor volumes was calculated according to the following formula: axb 2 /2, where a is the longer and b is the shorter dimension as described (13) . All the xenografts of HSC-3 Mock grew well (Fig. 1 Mock) and formed tumors of appreciable size by 27 days after xenografting (Fig. 2, A and B) , as would be expected in SCID mice. On the other hand, the rate of tumor implantation in vivo of HSC-3 BRAK cells (Fig.1 BRAK) was significantly suppressing effect of the drug was not observed in the case of BRAK non-expressing cells. Furthermore, introduction of small interference RNA expression-vector for BRAK into HSC-3 cells reduced both the expression levels of BRAK in HSC-3 cells and the antitumor efficacy of gefitinib in vivo. These data also indicate that BRAK expression is essential for tumor suppression in vivo (14) . The same or a higher level of natural killer (NK) cell activity is present in SCID mice compared with wild-type C.B-17 mice (26); and BRAK/CXCL14 stimulates the migration of activated NK cells but does not affect the proliferation or cytotoxic activity of normal NK cells (21) , suggesting that NK cells are partially responsible for BRAK/CXCL14-dependent tumor suppression and that the co-presence of a NK cell activator(s) is essential for tumor suppression. It is also reported that tumor angiogenesis is important for tumor growth and progression (4, 12, 23) and that BRAK/CXCL14 was shown to have angiostatic (anti-angiogenic) activity (17) . Thus, inhibition of tumor angiogenesis might be also important for the suppression of tumor progression.
In conclusion, this study indicates that expression of BRAK/CXCL14 in tumor cells suppresses the very early stage of tumor establishment in SCID mouse xenografts, suggesting the possibility that BRAK/CXCL14 expression inhibits tumor stem cell establishment by enhancing interactions between tumor stem cells and NK cells and/or by suppressing the formation of tumor microvessels. Our finding may be important for clarification of the molecular mechanisms of tumor suppression by this endogenous chemokine, BRAK/CXCL14.
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by 27 days after xenografting, whereas 20% of the nude mice retained tumors ( Table 1 ). The observed difference in the response to tumor cells between SCID and nude mice did not depend on variation in tumor cell preparation, but was due to the difference in the 2 mouse lines, because we performed these experiments simultaneously employing the same suspension of tumor cells. BRAK, which is a CXC type of chemokine, is also known as CXCL14. The chemokine was first reported to be expressed in the breast and kidney but later was found in many other normal cells and tissues (10) , whereas it was absent from or expressed in only a small amount in carcinoma cell lines in culture and cancerous tissues in vivo including OC cells (5, 7, 9, 17) . It was reported that mouse BRAK/CXCL14 activates B cells and monocytes (20) and stimulates dendritic cell infiltration into normal and tumor tissues (18) . BRAK/CXCL14 also stimulates the migration of activated NK cells (21) and inhibits angiogenesis (17) . Accumulating evidence indicates that cancers grow from cancer stem cells (24) and that tumors progress by interacting with the tumor microenvironment, which is composed of stroma, inflammatory cells and recruited vasculature (3). The nude mouse lacks a thymus, which is essential for the production of T-cells; and SCID mouse is deficient in both B-cells and T-cells, and thus easily accepts tissues from other species (8) . In fact, the growth of human tumor xenografts is the same or much greater in the SCID mouse than in nude mouse (11, 15) . This tendency was also seen in our data on HSC-3 Mock cells, whereas in the case of HSC-3 BRAK cells, the implantability of xenografts was quite different between the 2 strains, being much greater in the nude mice (Table 1) . Recently we found that oral administration of gefitinib, an inhibitor of epidermal growth factor receptor, significantly (P < 0.001) reduced tumor growth of xenografts of 3 HNSCC cell lines (HSC-2, HSC-3 and HSC-4), accompanied by increase in BRAK expression specifically in tumor tissue. This tumor- The same mixture of BRAK-expressing (BRAK) or mock vector-transfected (Mock) cells (5 × 10 6 /site) was subcutaneously inoculated into both sides of back region of 10 female SCID or Nude mice. Size of tumors was measured every 3 or 4 days. Tumors were regarded as nonimplanted when the tumor size was less than 5 mm 3 .
